EP3976038A4 - Composés hétérocycliques en tant qu'inhibiteurs de prmt5 - Google Patents
Composés hétérocycliques en tant qu'inhibiteurs de prmt5 Download PDFInfo
- Publication number
- EP3976038A4 EP3976038A4 EP20814821.3A EP20814821A EP3976038A4 EP 3976038 A4 EP3976038 A4 EP 3976038A4 EP 20814821 A EP20814821 A EP 20814821A EP 3976038 A4 EP3976038 A4 EP 3976038A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- heterocyclic compounds
- prmt5 inhibitors
- prmt5
- inhibitors
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962854435P | 2019-05-30 | 2019-05-30 | |
US202062966337P | 2020-01-27 | 2020-01-27 | |
PCT/US2020/034711 WO2020243178A1 (fr) | 2019-05-30 | 2020-05-27 | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3976038A1 EP3976038A1 (fr) | 2022-04-06 |
EP3976038A4 true EP3976038A4 (fr) | 2023-07-12 |
Family
ID=73553050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20814821.3A Withdrawn EP3976038A4 (fr) | 2019-05-30 | 2020-05-27 | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3976038A4 (fr) |
JP (1) | JP2022534998A (fr) |
KR (1) | KR20220016194A (fr) |
CN (1) | CN114126614A (fr) |
AU (1) | AU2020283505A1 (fr) |
CA (1) | CA3141855A1 (fr) |
WO (1) | WO2020243178A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202406908A (zh) * | 2022-08-09 | 2024-02-16 | 大陸商上海湃隆生物科技有限公司 | 新型prmt5抑制劑及其應用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017212385A1 (fr) * | 2016-06-06 | 2017-12-14 | Pfizer Inc. | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux |
WO2019112719A1 (fr) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202321249A (zh) * | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
WO2018065365A1 (fr) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
US11220524B2 (en) * | 2017-02-20 | 2022-01-11 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
US10570140B2 (en) * | 2017-08-09 | 2020-02-25 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
RS63623B1 (sr) * | 2017-12-13 | 2022-10-31 | Lupin Ltd | Supstituisana biciklična heterociklična jedinjenja kao inhibitori prmt5 |
CA3108388A1 (fr) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
-
2020
- 2020-05-27 CA CA3141855A patent/CA3141855A1/fr active Pending
- 2020-05-27 EP EP20814821.3A patent/EP3976038A4/fr not_active Withdrawn
- 2020-05-27 WO PCT/US2020/034711 patent/WO2020243178A1/fr unknown
- 2020-05-27 KR KR1020217043087A patent/KR20220016194A/ko not_active Application Discontinuation
- 2020-05-27 JP JP2021570954A patent/JP2022534998A/ja active Pending
- 2020-05-27 CN CN202080052198.1A patent/CN114126614A/zh active Pending
- 2020-05-27 AU AU2020283505A patent/AU2020283505A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017212385A1 (fr) * | 2016-06-06 | 2017-12-14 | Pfizer Inc. | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux |
WO2019112719A1 (fr) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 |
Non-Patent Citations (2)
Title |
---|
RUIFENG MAO ET AL: "Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 14, 26 June 2017 (2017-06-26), US, pages 6289 - 6304, XP055682728, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00587 * |
See also references of WO2020243178A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN114126614A (zh) | 2022-03-01 |
CA3141855A1 (fr) | 2020-12-03 |
WO2020243178A1 (fr) | 2020-12-03 |
EP3976038A1 (fr) | 2022-04-06 |
KR20220016194A (ko) | 2022-02-08 |
AU2020283505A1 (en) | 2021-12-23 |
JP2022534998A (ja) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3752491A4 (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
IL274762A (en) | Novel heterocyclic compounds as PRMT5 inhibitors | |
IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
EP3833355A4 (fr) | Inhibiteurs de prmt5 | |
EP3919055A4 (fr) | Composé hétérocyclique | |
EP3997070A4 (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de bet | |
EP3896060A4 (fr) | Composé hétérocyclique | |
EP3895707A4 (fr) | Composé hétérocyclique | |
EP3822276A4 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de trk | |
EP3720495A4 (fr) | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 | |
EP4067359A4 (fr) | Composés de pyrimidoimidazole utilisés en tant qu'inhibiteurs de la dna-pk | |
EP4077282A4 (fr) | Inhibiteurs de prmt5 | |
EP3873474A4 (fr) | Composés hétérocycliques utilisés comme inhibiteurs de bet | |
EP3833669A4 (fr) | Inhibiteurs de prmt5 | |
EP3697787A4 (fr) | Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase | |
EP4066893A4 (fr) | Composé hétérocyclique | |
EP3666770A4 (fr) | Nouveaux composés hétérocycliques comme inhibiteurs de cdk8/19 | |
EP3833668A4 (fr) | Inhibiteurs de prmt5 | |
EP3952865A4 (fr) | Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques | |
IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
EP3888652A4 (fr) | Composé hétérocyclique | |
EP3768671A4 (fr) | Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5 | |
EP4076459A4 (fr) | Inhibiteurs de prmt5 | |
EP4043450A4 (fr) | Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac | |
EP3844166A4 (fr) | Macrocycles substitués utiles en tant qu'inhibiteurs de kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031472500 Ipc: C07H0019140000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230609 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/00 20060101ALI20230602BHEP Ipc: A61P 35/00 20060101ALI20230602BHEP Ipc: C07D 498/04 20060101ALI20230602BHEP Ipc: C07D 487/04 20060101ALI20230602BHEP Ipc: C07D 519/00 20060101ALI20230602BHEP Ipc: C07H 19/14 20060101AFI20230602BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231201 |